+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Antidepressant Drugs Market Forecast up to 2018–2024

  • ID: 4655529
  • Report
  • Region: Global
  • 104 Pages
  • Infoholic Research LLP
1 of 5
Increase in the Prevalence of Depression and Growing Awareness Levels About the State of the Disease Will Drive the Market

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan PLC
  • AstraZeneca PLC
  • Eli Lilly & Company Ltd.
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • MORE

Depression is a serious mental illness affecting more than 350 million people globally. This is also known as “major depression disorder” or “unipolar depression”. According to a report by the Psychiatric Association, nearly 14.8 million adults in the US are suffering from depression. An ageing population and the increasing prevalence of depression are the primary factors driving the global antidepressant drugs market growth. Supportive initiatives from the government and other organizations and increasing clinical trials will provide an opportunity for the market growth in the future.

At the global level, over 300 million people are estimated to suffer from depression, which is equivalent to 4.4% of the world’s total population. Only less than 10% of the affected people are treated although there is the availability of branded and effective treatments for depression. The challenges for effective care include lack of capitals, unavailability of qualified health-care providers, and public stigma associated with mental disorders. Along with these, imprecise assessment of the condition is also a challenge faced globally.

The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the antidepressant drugs market, followed by Europe, Asia Pacific, and Rest of the World. North America alone occupies more than 30% of the market, with a significant contribution from the US to market growth.

Based on the drug class, the market is segmented into selective serotonin reuptake inhibitors (SSRIs), norepinephrine–dopamine reuptake inhibitors (NDRI), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), and others. SSRIs are the most attractive drug in the market, owing to the highly effective treatment of depression and anxiety.

Key Players in this market are Novartis AG, Allergan Inc., Elli Lilly and Company, AstraZeneca plc, GSK, Otsuka Holdings Co., Ltd., and Johnson & Johnson are the key players in the market. The other prominent players include Pfizer, Shionogi & Co. Ltd., Abbott Laboratories, Takeda Pharmaceutical Co., Ltd., and H. Lundbeck A/S.

Government initiatives have been greatly changing the market scenario. Many initiatives are taken to increase awareness and reduce the suicide rate globally. Depression is confined by the mental health Gap Action Programme (mhGAP) of the World Health Organization (WHO) to assists countries to increase their facilities for those suffering from mental disorders, through special aid by healthcare workers. A special transitory is established by WHO for the treatment of depression. The companies are striving to develop innovative drugs to address the unmet needs in the market. For instance, in May 2018, Esketamine Nasal Spray of the Janssen Pharmaceutical Companies of Johnson & Johnson demonstrated rapid enhancements in depressive symptoms in patients with treatment-resistant depression in Phase III trials. Thus, this drug is expected to be one of the bestsellers in the market.

The report provides complete details about the usage and adoption rate of antidepressant drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan PLC
  • AstraZeneca PLC
  • Eli Lilly & Company Ltd.
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • MORE

1 Industry Outlook
1.1 Industry Overview
1.2 Industry Trends
1.3 Total Addressable Market

2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions

3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market
3.2.1 Trends in the Antidepressant Drugs Market
3.3 Related Markets
3.3.1 Neurosurgical Devices
3.3.2 Parkinson Drugs
3.3.2.1 Trends of Parkinson Diseases Market
3.3.3 Neurointerventional Devices
3.3.4 Over the Counter Drugs (OTC)

4 Market Outline
4.1 Antidepressant Drugs Pipeline
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis

5 Market Characteristics
5.1 Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing aging population
5.1.1.2 Increasing prevalence of Depression
5.1.2 Opportunities
5.1.2.1 Government Initiatives
5.1.2.2 Exhaustive Pipeline and Increasing Clinical Trials
5.1.3 Restraints
5.1.3.1 Complex drug development process
5.1.3.2 Adverse effects of antidepressant drugs
5.2 DRO – Impact Analysis
5.3 Key Stakeholders

6 Drug Class: Market Size and Analysis
6.1 Overview
6.2 Selective serotonin reuptake inhibitors (SSRIs)
6.3 Norepinephrine-dopamine reuptake inhibitor (NDRI)
6.4 Serotonin and norepinephrine reuptake inhibitors (SNRIs)
6.5 Monoamine oxidase inhibitors (MAOIs)
6.6 Tricyclic antidepressants (TCAs)
6.7 Others

7 Regions: Market Size and Analysis
7.1 Overview
7.2 North America
7.2.1 Overview
7.3 Europe
7.3.1 Overview
7.4 Asia Pacific
7.4.1 Overview
7.5 Rest of the World
7.5.1 Overview

8 Competitive Landscape

9 Vendor Profiles
9.1 AstraZeneca PLC
9.1.1 Overview
9.1.2 Business Units
9.1.3 Geographic Presence
9.1.4 Business Focus
9.1.5 SWOT Analysis
9.1.6 Business Strategies
9.2 Eli Lilly & Company Ltd.
9.2.1 Overview
9.2.2 Business Units
9.2.3 Geographic Revenue
9.2.4 Business Focus
9.2.5 SWOT Analysis
9.2.6 Business Strategies
9.3 GlaxoSmithKline plc
9.3.1 Overview
9.3.2 Business Units
9.3.3 Geographic Presence
9.3.4 Business Focus
9.3.5 SWOT Analysis
9.3.6 Business Strategies
9.4 Johnson & Johnson
9.4.1 Overview
9.4.2 Business Units
9.4.3 Geographic Revenue
9.4.4 Business Focus
9.4.5 SWOT Analysis
9.4.6 Business Strategies
9.5 Novartis AG
9.5.1 Overview
9.5.2 Business Units
9.5.3 Geographic Presence
9.5.4 Business Focus
9.5.5 SWOT Analysis
9.5.6 Business Strategy
9.6 Otsuka Holdings Co., Ltd.
9.6.1 Overview
9.6.2 Business Units
9.6.3 Geographic Revenue
9.6.4 Business Focus
9.6.5 SWOT Analysis
9.6.6 Business Strategies
9.7 Allergan PLC
9.7.1 Overview
9.7.2 Business Units
9.7.3 Geographic Revenue
9.7.4 Business Focus
9.7.5 SWOT Analysis
9.7.6 Business Strategies

10 Companies to Watch for
10.1 Pfizer, Inc.
10.1.1 Overview
10.1.2 Highlights
10.2 Takeda Pharmaceutical Co. Ltd.
10.2.1 Overview
10.2.2 Highlights
10.3 Shionogi & Co. Ltd.
10.3.1 Overview
10.3.2 Highlights
10.4 Abbott Laboratories
10.4.1 Overview
10.5 H. Lundbeck A/S
10.5.1 Overview

List of Tables
Table 1 Astrazeneca Plc: Offerings
Table 2 Astrazeneca Plc: Recent Developments
Table 3 Eli Lilly & Company Ltd.: Product Offerings
Table 4 Eli Lilly & Company Ltd.: Recent Developments
Table 5 Glaxosmithkline Plc: Offerings
Table 6 Glaxosmithkline Plc: Recent Developments
Table 7 Johnson & Johnson: Product Offerings
Table 8 Johnson & Johnson: Recent Developments
Table 9 Novartis Ag: Offerings
Table 10 Novartis Ag: Recent Developments
Table 11 Takeda Pharmaceutical Co. Ltd.: Overview
Table 12 Takeda Pharmaceutical Co. Ltd.: Recent Developments
Table 13 Shionogi & Co., Ltd.: Overview
Table 14 Shionogi & Co., Ltd.: Recent Developments

List of Figures
Chart 1 Research Methodology Of Global Antidepressant Drugs Market
Chart 2 Global Antidepressant Drugs Market Revenue, 2017-2024 ($Million)
Chart 3 Clinical Trials Of Neurointerventional Devices
Chart 4 Antidepressant Drugs Pipeline
Chart 5 Segmentation Of Global Antidepressant Drugs Market
Chart 6 Porter 5 Forces Of Antidepressant Drugs Market
Chart 7 Pest Analysis Of Antidepressant Drugs Market
Chart 8 Market Dynamics – Dro Analysis
Chart 9 World Population Aged 65 Years And Above, 1960–2060 (%)
Chart 10 Dro – Impact Analysis Of Global Antidepressant Drugs Market
Chart 11 Key Stakeholders
Chart 12 Antidepressant Drugs Market By Drug Type Segmentation, 2017-2024 ($Million)
Chart 13 Antidepressant Drugs Market Revenue By Products Type, 2017–2024 ($Million)
Chart 14 Selective Serotonin Reuptake Inhibitors (Ssris) Drugs Market By Types Segmentation, 2017-2024 ($Million)
Chart 15 Norepinephrine-Dopamine Reuptake Inhibitor (Ndri) Market By Types Segmentation, 2017-2024 ($Million)
Chart 16 Serotonin And Norepinephrine Reuptake Inhibitors (Snris) Drugs Market By Types Segmentation, 2017-2024 ($Million)
Chart 17 Monoamine Oxidase Inhibitors (Maois) Drugs Market By Types Segmentation, 2017-2024 ($Million)
Chart 18 Tricyclic Antidepressants (Tcas) Drugs Market By Types Segmentation, 2017-2024 ($Million)
Chart 19 Others Antidepressant Drugs Market By Types Segmentation, 2017-2024 ($Million)
Chart 20 Cases Of Depressive Disorder (Millions), By Who Region In 2017 (%)
Chart 21 Antidepressant Drugs Market By Regional Segmentation, 2017 Vs 2024 (%)
Chart 22 Antidepressant Drugs Market Revenue By Regions, 2017–2024 ($Million)
Chart 23 Antidepressant Drugs Market Revenue In North America, 2017-2024 ($Million)
Chart 24 Prevalence Of Chronic Depression, 2014
Chart 25 Antidepressant Drugs Market Revenue In Europe, 2017–2024 ($Million)
Chart 26 Antidepressant Drugs Market Revenue In Asia Pacific, 2017–2024 ($Million)
Chart 27 Antidepressant Drugs Market Revenue In Rest Of The World, 2017–2024 ($Million)
Chart 28 Astrazeneca Plc: Overview Snapshot
Chart 29 Astrazeneca Plc: Business Units
Chart 30 Astrazeneca Plc: Geographic Presence
Chart 31 Astrazeneca Plc: Swot Analysis
Chart 32 Eli Lilly & Company Ltd.: Overview Snapshot
Chart 33 Eli Lilly & Company Ltd.: Business Units
Chart 34 Eli Lilly & Company Ltd.: Geographic Revenue
Chart 35 Eli Lilly & Company Ltd.: Swot Analysis
Chart 36 Glaxosmithkline Plc: Overview Snapshot
Chart 37 Glaxosmithkline Plc: Business Units
Chart 38 Glaxosmithkline Plc: Geographic Presence
Chart 39 Glaxosmithkline Plc: Swot Analysis
Chart 40 Johnson & Johnson: Overview Snapshot
Chart 41 Johnson & Johnson: Business Units
Chart 42 Johnson & Johnson: Geographic Revenue
Chart 43 Johnson & Johnson: Swot Analysis
Chart 44 Novartis Ag: Overview Snapshot
Chart 45 Novartis Ag: Business Units
Chart 46 Novartis Ag: Geographical Presence
Chart 47 Novartis Ag: Swot Analysis
Chart 48 Otsuka Holdings Co., Ltd.: Offerings
Chart 49 Otsuka Holdings Co., Ltd.: Recent Developments
Chart 50 Otsuka Holdings Co., Ltd.: Overview Snapshot
Chart 51 Otsuka Holdings Co., Ltd.: Segmentation
Chart 52 Otsuka Holdings Co., Ltd.: Geographic Revenue
Chart 53 Otsuka Holdings Co., Ltd.: Swot Analysis
Chart 54 Allergan Plc: Offerings
Chart 55 Allergan Plc: Recent Developments
Chart 56 Allergan Plc: Overview Snapshot
Chart 57 Allergan Plc: Business Units
Chart 58 Allergan Plc: Geographic Revenue
Chart 59 Allergan Plc: Swot Analysis
Chart 60 Pfizer, Inc.: Recent Developments
Chart 61 Pfizer, Inc: Key Developments
Chart 62 Abbott Laboratories: Recent Developments
Chart 63 Abbott Laboratories: Key Developments
Chart 64 H. Lundbeck A/S: Overview
Chart 65 H. Lundbeck A/S: Recent Developments

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan PLC
  • AstraZeneca PLC
  • Eli Lilly & Company Ltd.
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • MORE

Depression is a serious mental illness affecting more than 350 million people globally. This is also known as “major depression disorder” or “unipolar depression”. According to a report by the Psychiatric Association, nearly 14.8 million adults in the US are suffering from depression. An ageing population and the increasing prevalence of depression are the primary factors driving the global antidepressant drugs market growth. Supportive initiatives from the government and other organizations and increasing clinical trials will provide an opportunity for the market growth in the future.

At the global level, over 300 million people are estimated to suffer from depression, which is equivalent to 4.4% of the world’s total population. Only less than 10% of the affected people are treated although there is the availability of branded and effective treatments for depression. The challenges for effective care include lack of capitals, unavailability of qualified health-care providers, and public stigma associated with mental disorders. Along with these, imprecise assessment of the condition is also a challenge faced globally.

The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the antidepressant drugs market, followed by Europe, Asia Pacific, and Rest of the World. North America alone occupies more than 30% of the market, with a significant contribution from the US to market growth.

Based on the drug class, the market is segmented into selective serotonin reuptake inhibitors (SSRIs), norepinephrine–dopamine reuptake inhibitors (NDRI), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), and others. SSRIs are the most attractive drug in the market, owing to the highly effective treatment of depression and anxiety.

Key Players in this market are Novartis AG, Allergan Inc., Elli Lilly and Company, AstraZeneca plc, GSK, Otsuka Holdings Co., Ltd., and Johnson & Johnson are the key players in the market. The other prominent players include Pfizer, Shionogi & Co. Ltd., Abbott Laboratories, Takeda Pharmaceutical Co., Ltd., and H. Lundbeck A/S.

Government initiatives have been greatly changing the market scenario. Many initiatives are taken to increase awareness and reduce the suicide rate globally. Depression is confined by the mental health Gap Action Programme (mhGAP) of the World Health Organization (WHO) to assists countries to increase their facilities for those suffering from mental disorders, through special aid by healthcare workers. A special transitory is established by WHO for the treatment of depression. The companies are striving to develop innovative drugs to address the unmet needs in the market. For instance, in May 2018, Esketamine Nasal Spray of the Janssen Pharmaceutical Companies of Johnson & Johnson demonstrated rapid enhancements in depressive symptoms in patients with treatment-resistant depression in Phase III trials. Thus, this drug is expected to be one of the bestsellers in the market.

The report provides complete details about the usage and adoption rate of antidepressant drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Note: Product cover images may vary from those shown
5 of 5
  • Abbott Laboratories
  • Allergan PLC
  • AstraZeneca PLC
  • Eli Lilly & Company Ltd.
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer, Inc.
  • Shionogi & Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4655529
Adroll
adroll